Literature DB >> 25977148

Association of Interleukin-10 -3575T>A and -1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis.

Yan Zhang1, Zu-Guang Xia2,3, Jin-Hong Zhu4, Min-Bin Chen1, Tong-Min Wang5, Wen-Xiang Shen6, Jing He7,8.   

Abstract

A number of studies have investigated the associations between IL-10 polymorphisms and non-Hodgkin lymphoma (NHL) susceptibility; however, the conclusions were still contradictory. To acquire a more precise estimation of the association, we performed the current meta-analysis. We systematically searched publications from EMBASE and MEDLINE, and calculated pooled odds ratios (ORs) and 95 % confidence intervals (CIs) using either fixed-effects or random-effects model. Genotype-based IL-10 mRNA expression analysis was performed using online public database of 270 individuals with three different ethnicities. A total of 10,703 cases and 11,823 controls from 10 studies were included for the -3575T>A polymorphism, 10,226 cases and 12,215 controls from 17 studies for the -1082A>G polymorphism. Pooled results indicated that IL-10 -3575T>A was associated with increased risk of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), especially for Caucasians and hospital-based population. There was no association between IL-10 -1082A>G and NHL risk. However, subgroup analysis showed that IL-10 -1082GG might confer increased susceptibility to FL. In summary, this meta-analysis indicated that -3575T>A polymorphism was associated with altered NHL susceptibility for Caucasians and hospital-based population, especially for DLBCL and FL subtypes. The -1082A>G polymorphism may contribute to increased FL risk. Further large-scale population studies among different ethnicities are needed to validate these results.

Entities:  

Keywords:  Interleukin-10; Meta-analysis; Non-Hodgkin lymphoma; Polymorphism

Mesh:

Substances:

Year:  2015        PMID: 25977148     DOI: 10.1007/s00438-015-1058-y

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  54 in total

Review 1.  Altered immunity as a risk factor for non-Hodgkin lymphoma.

Authors:  Andrew E Grulich; Claire M Vajdic; Wendy Cozen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03-02       Impact factor: 4.254

2.  Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations.

Authors:  Jing He; Li-Xin Qiu; Meng-Yun Wang; Rui-Xi Hua; Ruo-Xin Zhang; Hong-Ping Yu; Ya-Nong Wang; Meng-Hong Sun; Xiao-Yan Zhou; Ya-Jun Yang; Jiu-Cun Wang; Li Jin; Qing-Yi Wei; Jin Li
Journal:  Hum Genet       Date:  2012-02-28       Impact factor: 4.132

3.  Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma.

Authors:  L M Cunningham; C Chapman; R Dunstan; M C Bell; D J L Joske
Journal:  Leuk Lymphoma       Date:  2003-02

4.  Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.

Authors:  Marcello Persico; Mario Capasso; Eliana Persico; Mario Masarone; Amalia de Renzo; Daniela Spano; Savino Bruno; Achille Iolascon
Journal:  J Hepatol       Date:  2006-09-22       Impact factor: 25.083

5.  Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma.

Authors:  Martin Stern; Gerhard Opelz; Bernd Döhler; Christoph Hess
Journal:  Blood       Date:  2010-03-05       Impact factor: 22.113

6.  Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography.

Authors:  Dorothy Guzowski; Alamelu Chandrasekaran; Craig Gawel; Jacqueline Palma; Jonathan Koenig; Xue Ping Wang; Michael Dosik; Mark Kaplan; Charles C Chu; Sangeeta Chavan; Richard Furie; Emilia Albesiano; Nicholas Chiorazzi; Leslie Goodwin
Journal:  J Biomol Tech       Date:  2005-06

7.  Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.

Authors:  Pia Fernberg; Ellen T Chang; Kristina Duvefelt; Henrik Hjalgrim; Sandra Eloranta; Karina Meden Sørensen; Anna Porwit; Keith Humphreys; Mads Melbye; Karin Ekström Smedby
Journal:  Cancer Causes Control       Date:  2010-01-20       Impact factor: 2.506

8.  Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma.

Authors:  K Bogunia-Kubik; G Mazur; T Wróbel; K Kuliczkowski; A Lange
Journal:  Tissue Antigens       Date:  2008-02

9.  Interleukin 10 secretion in relation to human IL-10 locus haplotypes.

Authors:  J Eskdale; G Gallagher; C L Verweij; V Keijsers; R G Westendorp; T W Huizinga
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 10.  The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges.

Authors:  Andrew P Hutchins; Diego Diez; Diego Miranda-Saavedra
Journal:  Brief Funct Genomics       Date:  2013-08-12       Impact factor: 4.241

View more
  4 in total

1.  Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.

Authors:  Sarah Keppler; Susann Weiβbach; Christian Langer; Stefan Knop; Jordan Pischimarov; Miriam Kull; Thorsten Stühmer; Torsten Steinbrunn; Ralf Bargou; Hermann Einsele; Andreas Rosenwald; Ellen Leich
Journal:  Oncotarget       Date:  2016-06-21

Review 2.  NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies.

Authors:  Wen Fu; Zhen-Jian Zhuo; Yung-Chang Chen; Jinhong Zhu; Zhang Zhao; Wei Jia; Jin-Hua Hu; Kai Fu; Shi-Bo Zhu; Jing He; Guo-Chang Liu
Journal:  Oncotarget       Date:  2017-02-07

3.  Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP.

Authors:  Min Kyeong Kim; Kyong-Ah Yoon; Eun Young Park; Jungnam Joo; Eun Young Lee; Hyeon-Seok Eom; Sun-Young Kong
Journal:  Genomics Inform       Date:  2016-12-30

4.  Association of three promoter polymorphisms in interleukin-10 gene with cancer susceptibility in the Chinese population: a meta-analysis.

Authors:  Ping Wang; Junling An; Yanfeng Zhu; Xuedong Wan; Hongzhen Zhang; Shoumin Xi; Sanqiang Li
Journal:  Oncotarget       Date:  2017-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.